Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
08 août 2024 16h05 HE
|
Structure Therapeutics Inc.
GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter of 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in the fourth quarter...
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
07 juin 2024 16h05 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
05 juin 2024 19h53 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
03 juin 2024 16h09 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
03 juin 2024 07h30 HE
|
Structure Therapeutics Inc.
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the...
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
09 mai 2024 16h05 HE
|
Structure Therapeutics Inc.
Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human...
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
08 mars 2024 16h05 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
08 mars 2024 08h30 HE
|
Structure Therapeutics Inc.
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in...
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
18 déc. 2023 07h30 HE
|
Structure Therapeutics Inc.
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0%...
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
14 nov. 2023 16h10 HE
|
Structure Therapeutics Inc.
Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and...